Compared to the model group, long-term liraglutide treatment reduced blood glucose levels and significantly alleviated lipid metabolism disorders. Liraglutide also improved impaired cardiac function. Furthermore, the improvement in cardiac dysfunction was associated with reduced myocardial fibrosis in diabetic hearts, as evidenced by decreased expression of P4hα-1, COL-1, COL-3, MMP-1, and MMP-9. The gene discussed is MMP1; the disease is Myocardial fibrosis.